By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


SEARCH JOBS








Company News
Galectin Therapeutics To Host Webcast To Discuss Findings From Cohort 2 Of Phase 1 Clinical Trial Of GR-MD-02 In Fatty Liver Disease With Advanced Fibrosis 7/25/2014 8:00:03 AM
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014 11:20:42 AM
Galectin Therapeutics Added To Russell 2000 Index 7/9/2014 10:33:53 AM
Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 Is Efficacious In Preclinical Model Of Fatty Liver Disease With Fibrosis 6/23/2014 7:30:41 AM
Galectin Therapeutics To Present At Jefferies and Co. 2014 Global Healthcare Conference 5/29/2014 9:24:44 AM
Galectin Therapeutics Receives U.S. Patent For GR-MD-02 In Diabetic Nephropathy, A Progressive Kidney Disease 5/28/2014 9:15:23 AM
Galectin Therapeutics To Hold Conference Call To Provide Corporate Update Following Company's Annual Meeting Of Shareholders 5/8/2014 10:06:12 AM
Galectin Therapeutics Completes Enrollment Of Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH (Fatty Liver Disease) With Advanced Fibrosis 4/23/2014 9:21:44 AM
Galectin Therapeutics Announces First Patient Dosed In Second Cohort Of Phase 1 Trial Of GR-MD-02 For NASH With Advanced Fibrosis 4/17/2014 9:27:45 AM
First Cohort Results In Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence Of Therapeutic Effect On Fibrosis And Inflammation In Nash With Advanced Fibrosis 4/1/2014 11:03:25 AM
12345678910
//-->